Correction to: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations

  • PDF / 195,689 Bytes
  • 1 Pages / 595.276 x 790.866 pts Page_size
  • 15 Downloads / 173 Views

DOWNLOAD

REPORT


CORRECTION

Open Access

Correction to: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations Giovanni Ostuzzi1*, Davide Papola1, Chiara Gastaldon1, Georgios Schoretsanitis2, Federico Bertolini1, Francesco Amaddeo1, Alessandro Cuomo3, Robin Emsley4, Andrea Fagiolini3, Giuseppe Imperadore5, Taishiro Kishimoto6, Giulia Michencigh1, Michela Nosé1, Marianna Purgato1, Serdar Dursun7, Brendon Stubbs8,9, David Taylor10, Graham Thornicroft11, Philip B. Ward12, Christoph Hiemke13, Christoph U. Correll2,14,15 and Corrado Barbui1 Correction to: BMC Medicine 18, 215 (2020) https://doi.org/10.1186/s12916-020-01685-9 The original version of this article [1] unfortunately included an error to an author’s name. Author Serdar Dursun was erroneously presented as Dursun Serdar. The author name has been updated in the original article and included in the author list of this Correction. Author details 1 WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy. 2 Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA. 3Department of Molecular Medicine, University of Siena, Siena, Italy. 4Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg Campus, Cape Town 8000, South Africa. 5Azienda ULSS 9 Scaligera, Verona, Italy. 6Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. 7 Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada. 8 Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK. 9Physiotherapy Department, South London and Maudsley National Health Services Foundation Trust, London, UK. 10Pharmacy Department, Maudsley Hospital, London, UK. 11Centre for Global Mental Health and Centre for

Implementation Science, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. 12School of Psychiatry, UNSW Sydney and Schizophrenia Research Unit, Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia. 13Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany. 14 Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. 15Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.

Reference 1. Ostuzzi, et al. Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Medicine. 2020;18: 215 https://doi.org/10.1186/s12916-020-01685-9.

The original article can be found online at https://doi.org/10.1186/s12916020-01685-9. * Correspondence: [email protected] 1 WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Mov